ReviewCurrent oncology reports2026
Integrative Oncology for Biochemical Recurrence of Epithelial Ovarian Cancer.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clotrimazole Targets the c-Myc-Survivin Axis to Reduce the Viability of Ovarian Cancer Stem Cells Alone and in Combination with Chemotherapeutic Agents.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewBiochemical recurrence of epithelial ovarian cancer (EOC), defined as rising CA-125 levels without clinical or radiologic evidence of disease, is a frequent and challenging scenario. Cytotoxic therapy initiated at this stage does not improve survival and may diminish quality of life. This review evaluates integrative oncology (IO) interventions that may support women during this vulnerable period. RECENT
findingsMind-body therapies, including mindfulness, yoga, and cognitive behavioral therapy, have demonstrated benefits in reducing anxiety, distress, and fear of recurrence. Exercise and acupuncture improve vitality, mood, and sleep. Nutritional strategies-particularly anti-inflammatory diets, vitamin D sufficiency, and omega-3 fatty acid intake-promote resilience and overall health. Natural compounds such as green tea, medicinal mushrooms, modified citrus pectin, melatonin, and AHCC show immune-modulating or anti-tumor effects in preclinical or early clinical studies. Among repurposed non-oncologic drugs, metformin provides the strongest rationale, especially for women with type 2 diabetes. Although ovarian cancer-specific trials are limited, IO approaches are safe, feasible, and evidence-informed. They address psychosocial distress, improve quality of life, and may influence disease biology, offering meaningful options for women under surveillance during biochemical recurrence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.